CD8+ T cells need to be primed and activated toward effector CD8+ cytotoxic T lymphocytes, in a process called the tumor immunity cycle, in order to exert durable and efficient antitumor immune responses (Farhood et al., 2019). This evidence concerns the gene CD8A and neoplasm.